<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BENDROFLUMETHIAZIDE</span><br/>(ben-droe-floo-meth-eye'a-zide)<br/><span class="topboxtradename">Naturetin<br/></span><b>Classifications:</b> <span class="classification">fluid and water balance agent</span>; <span class="classification">thiazide diuretic</span><br/><b>Prototype: </b>Hydrochlorothiazide<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg, 10 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Thiazide diuretic chemically related to the sulfonamides. Similar to hydrochlorothiazide in pharmacologic action.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bendroflumethiazide decreases blood volume by increasing excretion of fluid and electrolytes. It has a hypotensive effect.</p>
<h1><a name="uses">Uses</a></h1>
<p>Management of edema associated with CHF, mild hypertension.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Lithium-associated diabetes insipidus.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Anuria, hypersensitivity to thiazides, sulfonamides; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal and hepatic disease; gout; diabetes mellitus.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.520 mg/d in 12 divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.050.4 mg/kg/d in 12 divided doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug early in a.m. after patient has eaten to reduce gastric irritation and prevent possibility of interrupted sleep
            due to diuresis. If 2 daily doses are ordered, administer second dose no later than 3 p.m.
         </li>
<li>Store tablets in tightly closed container at 15°30° C (59°86° F) unless otherwise specified.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> CV:</span> Orthostatic hypotension. <span class="typehead"> Metabolic:</span> Electrolyte imbalance, hypokalemia, hyperglycemia, impaired glucose tolerance, hyperuricemia. <span class="typehead">Musculoskeletal:</span> Exacerbation of gout. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cholestyramine,</b>
<b>colestipol</b> decrease absorption of the diuretic; <b>diazoxide</b> has additive effects; with <b>digoxin,</b> the hypokalemia may increase risk of <b>digitalis</b> toxicity; increases <b>lithium</b> levels and toxicity; may increase blood glucose levels, necessitating adjustment of hypoglycemic therapy (i.e., <span class="classification">sulfonylureas</span>), <b>insulin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 12 h. <span class="typehead">Peak:</span> 612 h. <span class="typehead">Duration:</span> 1824 h. <span class="typehead">Elimination:</span> Excreted unchanged in urine within 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP. Report a sudden fall in BP, which may initiate severe postural hypotension and potentially dangerous perfusion
            problems of the extremities, especially in older patients. Antihypertensive effects are generally noted in 34 d; maximal
            effects may require 34 wk.
         </li>
<li>Monitor I&amp;O ratio and pattern, and weight, particularly during first phase of antihypertensive therapy.</li>
<li>Lab tests: Periodic serum electrolytes. Report hypokalemia promptly.</li>
<li>Report unexplained onset of joint pain and limitation of motion; may be due to hyperuricemia since thiazides interfere with
            uric acid excretion, although thiazides rarely precipitate acute gout.
         </li>
<li>Monitor diabetics for loss of glycemic control.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Eat potassium-rich foods such as fruit juices, potatoes, cereals, skim milk, and bananas to prevent onset of hyperuricemia.</li>
<li>Make position changes slowly and in stages to avoid dizziness or fainting.</li>
<li>Report joint pain or limited joint movement.</li>
<li>Avoid OTC drugs unless approved by physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>